Janus kinase (JAK) and registry Archives

Abstract Number: 2874 • ACR/ARP Annual Meeting 2019
Comparison of Malignancy and Mortality Rates Between Tofacitinib and Biologic DMARDs in Clinical Practice: Five-Year Results from a US-Based Rheumatoid Arthritis Registry
Joel Kremer¹, Clifton Bingham ², Laura Cappelli ², Jeffrey Greenberg ³, Ann Madsen ⁴, Jamie Geier ⁴, Jose L. Rivas ⁵, Alina Onofrei ⁶, Christine Barr ⁶, Dimitrios Pappas ⁷, Heather Litman ⁶, Kimberly Dandreo ⁶, Andrea Shapiro ⁸, Carol Connell ⁹ and Arthur Kavanaugh ¹⁰, ¹Albany Medical College, Albany, NY, ²Johns Hopkins University, Baltimore, MD, ³Corrona, LLC; NYU School of Medicine, Waltham, MA, ⁴Pfizer Inc, New York, NY, ⁵Pfizer SLU, Madrid, Spain, ⁶Corrona, LLC, Waltham, MA, ⁷Columbia University, New York, NY, ⁸Pfizer Inc, Peapack, NJ, ⁹Pfizer Inc, Groton, CT, ¹⁰University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: Real-world evidence (RWE) is key to understanding post-approval long-term safety of medications. Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA.…

Abstracts tagged "Janus kinase (JAK) and registry"